Head-to-Head diabetes drug trial aims to prevent heart attacks and kidney damage

This large, completed study directly compared two common type 2 diabetes medications—dapagliflozin and metformin—to see which one is better at preventing serious long-term health problems. It involved over 2,000 adults with early-stage diabetes who were either new to medication or on one other drug. Researchers tracked participants for about four years using national health records to see which drug led to fewer heart attacks, strokes, kidney issues, and deaths.